GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

With the new operations site and logistics center in Sydney, “Australian researchers and biotech companies will no longer ...

Vera Therapeutics appointed Amgen and Seagen alum Matt Skelton as EVP of commercial. Frank Lane was appointed SVP and head of ...

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Legend Biotech (LEGN – Research Report) and keeping the price ...

BMO Capital analyst Kostas Biliouris reiterated a Buy rating on Legend Biotech (LEGN – Research Report) yesterday and set a price target of $90.00. Kostas Biliouris’s rating is based on several ...

Legend Biotech Corporation (NASDAQ:LEGN) Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Ladies and gentlemen, ...

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.

Ladies and gentlemen, thank you for standing by. Welcome to Legend Biotech reports third quarter 2024 financial results. (Operator Instructions) Please be advised that today's conference is being ...

CARVYKTI demonstrated a 45% reduction in the risk of death compared to standard therapies in multiple myeloma patients.

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

Shares of Legend Biotech Corporation Sponsored ADR (LEGN) have been struggling lately and have lost 9.8% over the past week.